Premium
CSF hypocretin measures in patients with obstructive sleep apnea
Author(s) -
Kanbayashi T.,
Inoue Y.,
Kawanishi K.,
Takasaki H.,
Aizawa R.,
Takahashi K.,
Ogawa Y.,
Abe M.,
Hishikawa Y.,
Shimizu T.
Publication year - 2003
Publication title -
journal of sleep research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 117
eISSN - 1365-2869
pISSN - 0962-1105
DOI - 10.1046/j.0962-1105.2003.00373.x
Subject(s) - narcolepsy , obstructive sleep apnea , cataplexy , excessive daytime sleepiness , orexin , medicine , cerebrospinal fluid , sleep disorder , sleep apnea , sleep (system call) , apnea , psychology , anesthesia , neuropeptide , psychiatry , neurology , insomnia , receptor , computer science , operating system
Summary The majority of patients with narcolepsy‐cataplexy were reported to have very low cerebrospinal fluid (CSF) hypocretin‐1 (orexin‐A) levels. The hypocretin‐1 levels of secondary excessive daytime sleepiness (EDS) disorders are not known. In this study, we found that CSF hypocretin levels in the patients with obstructive sleep apnea syndrome were within the control range. The low hypocretin levels seem to reflect only the presence of cataplexy and DR2 positive in narcoleptics but not EDS itself.